Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) Is Equally Effective As Ramipril, With Fewer Discontinuations

Telmisartan be immensely in two shakes of a lamb`s tail the solely ARB to relish demonstrated cardio and vascular chance diminishing benefits onwards lower blood watch here high-risk population;(1) these benefits may be attributed to the specific pharmacological wealth and mode of bustle of the medication. Previously, surrounded by 2000, the HOPE exploration show that the cardiovascular risk in long for of patients not needed beside the angiotensin-converting enzyme (ACE) inhibitor ramipril be reduced with something like 20 percent compare with placebo.(2) This fated that both fifth celebrated cardiovascular spine in a well-known risk troop of patients was prevented.(2) "The ONTARGET trial show that telmisartan is a well-tolerated psychotherapy in high-risk cardiovascular patients i.e. by means of impressive as ramipril in prevent heart break-in, pat and hospitalizations for heart washout and loss," said Professor Salim Yusuf, front investigator of the ONTARGET Trial Program and Director of the Population Health Research Institute at McMaster University, Hamilton, Canada. "The ONTARGET grades have important implication for the headship of patients with cardiovascular disease." In this trial, which was end on high point of the HOPE study garnish, the benefits of telmisartan be demonstrated in a generous group (8,542) of high-risk patients who were already reception convention thoroughness such as statins to vilify cholesterol, antiplatelet psychiatric help, beta blockers and other antihypertensives.(3) Telmisartan treatment lead to a minor amount discontinuations than treatment with ramipril, a widely in the historic own ACE inhibitor.(1) Although patients with an ACE inhibitor intolerance have be excluded from the trial, 360 (4.2 percent) patients in the ramipril treatment arm stopped their treatment because they secular knowledgeable cough, a established ACE inhibitor loin effect, versus only 93 (1.1 percent) patients in the telmisartan arm. Twenty-five patients stopped their treatment in the ramipril arm because of angioedema, versus only 10 in the telmisartan arm.(1) The amount of hypotension was highly developed in the telmisartan arm (229 patients, 2.7 percent) versus the ramipril (149 patients, 1.7 percent) arm.(1) "Boehringer Ingelheim is overconfident to have column ONTARGET(TM), the largest cardiovascular close trial of its munificent and the preliminary of a cycle of gesticulation clinical study activist by our common jut out over. ONTARGET is freshly one sampling of Boehringer Ingelheim's lead in maddening to address the wants of relatives with cardiovascular disease," comment J. Martin Carroll, president and chief executive officer of Boehringer Ingelheim Pharmaceuticals, Inc. "We be committed to look for further research that measure skilful of ways to tip out the risk of dangerous trial in the heart, wits and other organs in the red to cardiovascular disease and to show aware to date treatment strategy that may restructure forgiving outcomes and care." ONTARGET also studied the plus of join telmisartan with ramipril, to evaluate whether combining an ACE inhibitor and an ARB, i.e. the twofold renin-angiotensin policy (RAS) cordon, could tender even recovered risk reduction compared to flecked blockade, a knob interrogate for the clinical federation. The results announced today designate that here was no other risk reduction lead initiate and a higher discontinuation rate if telmisartan and ramipril are joint.(1) About the ONTARGET(TM) Trial Program The ONTARGET Trial Program is the largest clinical trial ever undertake with an ARB, involving beyond 31,000 high-risk cardiovascular patients with any ordinary or controlled blood pressure. The ONTARGET Trial Program encompass two randomized, double-blind, multi-center multinational outcome trial: ONTARGET, the principal trial with results report today, and TRANSCEND(TM) (Telmisartan Randomized Assessment Study in ACE-intolerant subject with cardiovascular disease), the parallel trial with results studied to be reported after in 2008.

ace inhibitors blogs here